Christopher Paul German - 10 Jun 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Signature
/s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German
Issuer symbol
RYTM
Transactions as of
10 Jun 2025
Net transactions value
-$119,806
Form type
4
Filing time
12 Jun 2025, 16:50:02 UTC
Previous filing
24 Mar 2025
Next filing
11 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
German Christopher Paul Corporate Controller & CAO 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German 12 Jun 2025 0001260835

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $19,210 +1,069 +37% $17.97 3,958 10 Jun 2025 Direct
transaction RYTM Common Stock Sale $139,016 -2,069 -52% $67.19 1,889 10 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Options (Right to Buy) Options Exercise $0 -1,069 -11% $0.000000 8,231 10 Jun 2025 Common Stock 1,069 $17.97 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025
F2 The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.